Akers Biosciences Announces $6.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
August 11, 2020 08:00 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), today announced that it has entered into definitive agreements with several...
Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP
May 14, 2020 09:33 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Premas...
Akers Biosciences and Premas Biotech Announce Successful Expression of Coronavirus Antigens
April 08, 2020 09:25 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, April 08, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its...
Akers Biosciences Announces $4.6 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
April 07, 2020 10:53 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, April 07, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has...
Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Candidate
March 24, 2020 16:06 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, March 24, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced it will hold a...